Latest Nuchev (ASX:NUC) News

Nuchev Limited has transitioned from an agency to a distribution model with H&S Global, aiming to enhance margins and scale growth across key wellness brands.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

Nuchev Limited has locked in a $2 million unsecured working capital facility from major shareholders, aiming to fuel its expansion and push towards profitability in the near term.

Nuchev Limited reported a strong FY25 with revenue doubling to $22.9 million, driven by growth in Oli6® Nutritionals and the integration of bWellness Practitioner channel. Adjusted EBITDA loss narrowed significantly amid improved margins and cost control.

Nuchev Limited reported a remarkable FY25 with revenue doubling to $22.9 million, driven by strong growth in Oli6® Nutritional sales and the acquisition of bWellness. The company improved margins, reduced losses, and expanded into new international markets including Vietnam.

H&S Group has exercised performance options to increase its stake in Nuchev Limited to 48.62%, injecting $1.9 million and enhancing Nuchev’s financial flexibility for growth.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Nuchev Limited has entered an exclusive sales agency agreement with Brauer Natural Medicines and H&S Brand Corporation, expanding its footprint in Australia's natural and complementary medicines sector. The deal covers key brands including Brauer, Skin Physics, and Rapid Loss, with potential for broader ANZ distribution.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

Nuchev Limited has appointed Nathan Cheong as its new CEO, with current CEO Mick Myers transitioning to COO and CFO roles, signaling a strategic leadership evolution.